Dilated Cardiomyopathy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Dilated Cardiomyopathy - Pipeline Review, H2 2016

Dilated Cardiomyopathy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Dilated Cardiomyopathy - Pipeline Review, H2 2016
Published Jul 20, 2016
60 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Dilated Cardiomyopathy - Pipeline Review, H2 2016, provides an overview of the Dilated Cardiomyopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy
- The report reviews pipeline therapeutics for Dilated Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dilated Cardiomyopathy therapeutics and enlists all their major and minor projects
- The report assesses Dilated Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dilated Cardiomyopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dilated C

  
Source:
Document ID
GMDHC8247IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Dilated Cardiomyopathy Overview61
Therapeutics Development71
  Pipeline Products for Dilated Cardiomyopathy Overview71
Dilated Cardiomyopathy Therapeutics under Development by Companies81
Dilated Cardiomyopathy Pipeline Products Glance93
  Clinical Stage Products91
  Early Stage Products101
  Unknown Stage Products111
Dilated Cardiomyopathy Products under Development by Companies121
Dilated Cardiomyopathy Companies Involved in Therapeutics Development136
  Array BioPharma Inc.131
  Capricor Therapeutics, Inc.141
  Hemostemix Ltd151
  Kasiak Research Private Limited161
  Sanofi171
  Vericel Corporation181
Dilated Cardiomyopathy Therapeutics Assessment199
  Assessment by Monotherapy Products191
  Assessment by Target202
  Assessment by Mechanism of Action222
  Assessment by Route of Administration242
  Assessment by Molecule Type262
Drug Profiles2821
  ACP-01 Drug Profile283
  ARRY-797 Drug Profile312
  CAP-1002 Drug Profile335
  CIP-137401 Drug Profile381
  Drugs for Dilated Cardiomyopathy Drug Profile391
  ixmyelocel-T Drug Profile407
  MYK-491 Drug Profile471
  Refacell-DCM Drug Profile481
Dilated Cardiomyopathy Dormant Projects491
Dilated Cardiomyopathy Product Development Milestones509
  Featured News &Press Releases501
    Apr 04, 2016: Results from Vericel Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented at ACC and Published in The Lancet501
    Mar 29, 2016: Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions511
    Mar 28, 2016: Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy511
    Mar 10, 2016: Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy521
    Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T531
    Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia531
    Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack531
    Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T541
    Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting541
    May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients551
    May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions561
    Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T561
    Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy571
    Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy581
    May 17, 2011: Aastrom To Present Results From Two Studies of Ixmyelocel-T At International Society For Cellular Therapy Meeting581
Appendix592
  Methodology591
  Coverage591
  Secondary Research591
  Primary Research591
  Expert Panel Validation591
  Contact Us591
  Disclaimer601

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Dilated Cardiomyopathy - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dilated-Cardiomyopathy-Pipeline-Review-H2-2016-2088-16221>
  
APA:
Global Markets Direct - Market Research. (2016). Dilated Cardiomyopathy - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Dilated-Cardiomyopathy-Pipeline-Review-H2-2016-2088-16221>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.